Larimar Therapeutics (NASDAQ:LRMR) Stock: Insider Gopi Shankar Acquires 5,000 Shares

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) insider Gopi Shankar bought 5,000 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average price of $2.71 per share, with a total value of $13,550.00. Following the purchase, the insider directly owned 81,443 shares of the company’s stock, valued at $220,710.53. The trade was a 6.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Larimar Therapeutics Price Performance

Shares of LRMR traded up $0.32 on Friday, hitting $3.02. The company’s stock had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. The company has a market capitalization of $313.72 million, a PE ratio of -1.55 and a beta of 0.73. Larimar Therapeutics, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $6.42. The company has a 50 day moving average price of $2.93 and a 200 day moving average price of $3.76.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wedbush restated an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Leerink Partners initiated coverage on Larimar Therapeutics in a research note on Monday, September 14th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.33.

Check Out Our Latest Analysis on LRMR

Hedge Funds Weigh In On Larimar Therapeutics

Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Larimar Therapeutics during the 2nd quarter worth $17,318,000. AIGH Capital Management LLC bought a new position in Larimar Therapeutics in the 3rd quarter valued at $5,911,000. Dimensional Fund Advisors LP boosted its position in Larimar Therapeutics by 143.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after buying an additional 470,968 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Larimar Therapeutics by 148.9% in the 1st quarter. Renaissance Technologies LLC now owns 739,942 shares of the company’s stock valued at $3,330,000 after buying an additional 442,676 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at $1,210,000. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Larimar Therapeutics

These are some of the LRMR stories that stood out recently:

  • Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
  • Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Featured Articles

Insider Buying and Selling by Quarter for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.